Rydex Biotechnology Fund Class C
RYCFX
NASDAQ
| Weiss Ratings | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Company Info | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | Rydex Funds | |||
| Manager/Tenure (Years) | Michael P. Byrum (27), Adrian Bachman (3), Brendan Cain (3), 2 others | |||
| Website | http://www.guggenheiminvestments.com | |||
| Fund Information | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | Rydex Biotechnology Fund Class C | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Technology | |||
| Inception Date | Mar 30, 2001 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | 2,500.00 | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | 0.01 | |||
| Dividends and Shares | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 0.00% | |||
| Dividend | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.77% | |||
| Asset Allocation | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 0.15% | |||
| Stock | 99.97% | |||
| U.S. Stock | 94.96% | |||
| Non-U.S. Stock | 5.01% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 0.00% | |||
| Convertible | 0.00% | |||
| Other Net | -0.12% | |||
| Price History | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.05% | |||
| 30-Day Total Return | 5.75% | |||
| 60-Day Total Return | 11.75% | |||
| 90-Day Total Return | 18.20% | |||
| Year to Date Total Return | 29.50% | |||
| 1-Year Total Return | 19.44% | |||
| 2-Year Total Return | 41.04% | |||
| 3-Year Total Return | 26.21% | |||
| 5-Year Total Return | 19.16% | |||
| Price | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | -- | |||
| 1-Month High Price | -- | |||
| 52-Week Low Price | -- | |||
| 52-Week Low Price (Date) | -- | |||
| 52-Week High Price | -- | |||
| 52-Week High Price (Date) | -- | |||
| NAV | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $52.59 | |||
| 1-Month Low NAV | $48.72 | |||
| 1-Month High NAV | $53.71 | |||
| 52-Week Low NAV | $34.91 | |||
| 52-Week Low NAV (Date) | Apr 08, 2025 | |||
| 52-Week High NAV | $53.80 | |||
| 52-Week High Price (Date) | Dec 02, 2024 | |||
| Beta / Standard Deviation | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.80 | |||
| Standard Deviation | 16.66 | |||
| Balance Sheet | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 117.49M | |||
| Operating Ratios | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 2.38% | |||
| Turnover Ratio | 79.00% | |||
| Performance | RYCFX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 14.45% | |||
| Last Bear Market Total Return | -10.45% | |||